Idexx Laboratories (IDXX) Liabilities and Shareholders Equity (2009 - 2026)

Idexx Laboratories has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $3.4 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 3.35% year-over-year to $3.4 billion in Q2 2026; TTM through Jun 2026 was $13.6 billion, a 2.86% increase from a year earlier, with the FY2025 full-year figure at $3.4 billion, up 1.74% from the prior year.
• Liabilities and Shareholders Equity was $3.4 billion for Q2 2026 at Idexx Laboratories, up from $3.4 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $3.4 billion in Q2 2026, with the low at $2.6 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $3.1 billion, with a median of $3.3 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity advanced 19.41% in 2024, then fell 4.17% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.7 billion in 2022, then gained by 18.68% to $3.3 billion in 2023, then rose by 1.03% to $3.3 billion in 2024, then climbed by 1.74% to $3.4 billion in 2025, then rose by 2.73% to $3.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $3.4 billion (Q2 2026), $3.4 billion (Q1 2026), and $3.4 billion (Q4 2025), per Business Quant data.